None listed
Conditions
Brief summary
The proposed study is to investigate whether neutrophils are affected by dual antiplatelet therapy. Platelets are blood clotting cells that usually act to repair damage to blood vessels. However, platelets also cause blood clotting in the arteries of the heart which can cause a heart attack. As such, dual antiplatelet therapy is the gold standard pharmacological management of a heart attack, which inhibits platelet activity to reduce the risk of recurrent cardiovascular events. Despite antiplatelet therapy, nearly a third of New Zealander’s will experience all-cause death, recurrent acute coronary syndrome (unstable angina or a heart attack), or will be readmitted to hospital due to their cardiovascular disease within 12 months of their heart attack. This recurrence is partially attributable to persistent platelet activity, although several studies have demonstrated that antiplatelet medications also elicit off-target effects on immune cells, which are known to be important for recovery after a heart attack. Neutrophils are the first type of immune cells to arrive to the site of cardiac injury after a heart attack, where they perform a variety of biological processes to clear debris and help recovery. Notably, the effects of antiplatelet therapy on neutrophils is understudied. Therefore we aim to investigate whether current antiplatelet medications have off-target effects on neutrophils. We hypothesise that dual anti-platelet therapy will affect neutrophil function.
Interventions
Dual antiplatelet therapy (DAPT): Acetylsalicylic acid (Aspirin) and ticagrelor.
The proposed study is to investigate whether neutrophils are affected by dual antiplatelet therapy.
Participants will receive DAPT (oral tablets) for a total of seven days. Participants will receive a combination of Acetylsalicylic acid (300 mg loading dose on day 1, 100 mg maintenance dose on days 2 – 7) and ticagrelor (180 mg loading dose on day 1, 90 mg maintenance dose on days 1 – 7). This treatment regime mi
Dual antiplatelet therapy (DAPT): Acetylsalicylic acid (Aspirin) and ticagrelor. The proposed study is to investigate whether neutrophils are affected by dual antiplatelet therapy. Participants will receive DAPT (oral tablets) for a total of seven days. Participants will receive a combination of Acetylsalicylic acid (300 mg loading dose on day 1, 100 mg maintenance dose on days 2 – 7) and ticagrelor (180 mg loading dose on day 1, 90 mg maintenance dose on days 1 – 7). This treatment regime mimics the routine administration of DAPT for acute myocardial infarction (AMI) patients in Aotearoa New Zealand. Adherence to medication will be recorded by participants (date and time of dose) and checked by the study researchers at each study visit. Participants are also informed that non-adherence at any point during the 7 day study period will result in withdrawal from the study. After Day 1 (loading doses), participants will self-administer DAPT and record timing and dates of each dose in a provided form. Participants can also choose to be notified when it is time to take their next dose of DAPT.
Sponsors
Victoria University of Wellington
Study design
Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
Self-reporting healthy individuals.
Exclusion criteria
Pre-existing immune, cardiovascular or platelet disorders, diabetes mellitus, active malignancy, pregnancy, acute illness or vaccination within six weeks prior to recruitment, treatment with cardiovascular or immune-modulating medications within seven days prior to recruitment, or a previous adverse drug reaction to either Acetylsalicylic acid or ticagrelor.
Outcome results
None listed